Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.41 and has seen 2.13 million shares traded in the last trading session. The ADAP stock price is -215.38% off its 52-week high price of $2.05 and 18.46% above the 52-week low of $0.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.95 million shares traded. The 3-month trading volume is 2.11 million shares.
The consensus among analysts is that Adaptimmune Therapeutics Plc ADR (ADAP) is Buy stock at the moment, with a recommendation rating of 1.89. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Sporting 0.66% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADAP stock price touched $0.65 or saw a rise of 5.11%. Year-to-date, Adaptimmune Therapeutics Plc ADR shares have moved 21.46%, while the 5-day performance has seen it change 18.10%. Over the past 30 days, the shares of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have changed -2.95%. Short interest in the company has seen 5.35 million shares shorted with days to cover at 4.71.
Wall Street analysts have a consensus price target for the stock at $4, which means that the shares’ value could jump 83.75% from current levels. The projected low price target is $4.0 while the price target rests at a high of $4.0. In that case, then, we find that the current price level is -515.38% off the targeted high while a plunge would see the stock gain -515.38% from current levels.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Figures show that Adaptimmune Therapeutics Plc ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -45.48% over the past 6 months, with this year growth rate of 77.78%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 204.90%.
9 analysts offering their estimates for the company have set an average revenue estimate of 8.83M for the current quarter. 3 have an estimated revenue figure of 6.3M for the next ending quarter. Year-ago sales stood 231k and 5.68M respectively for this quarter and the next, and analysts expect sales will grow by 3,721.55% for the current quarter and 204.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.30% over the past 5 years.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Insiders own 0.38% of the company shares, while shares held by institutions stand at 60.27% with a share float percentage of 60.49%. Investors are also buoyed by the number of investors in a company, with Adaptimmune Therapeutics Plc ADR having a total of 95.0 institutions that hold shares in the company. The top two institutional holders are MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares worth more than $38.0 million. As of 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP held 16.1135% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 27.4 million shares as of 2024-06-30. The firm’s total holdings are worth over $26.72 million and represent 11.3299% of shares outstanding.
